Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 100 of 372 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/07/23
End: 12/01/26
Due: 12/01/27
Phase: N/A
Priority: Normal
Start: 07/01/15
End: 02/06/24
Due: 02/06/25
Phase: N/A
Priority: Normal
Start: 09/30/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/10
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/15/11
End: 02/24/20
Due: 02/24/21
Phase: N/A
Priority: Normal
Start: 09/30/04
End: 06/30/09
Due: 06/30/10
Phase: N/A
Priority: Normal
Start: 03/31/01
End: 05/31/09
Due: 05/31/10
Phase: N/A
Priority: Normal
Start: 02/28/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/31/12
End: 09/30/13
Due: 09/30/14
Phase: N/A
Priority: Normal
Start: 04/12/19
End: 04/25/19
Due: 04/25/20
Phase: N/A
Priority: Normal
Start: 05/04/04
End: 05/15/08
Due: 05/15/09
Phase: N/A
Priority: Normal
Start: 12/26/13
End: 01/09/17
Due: 01/09/18
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Phase: N/A
Priority: Normal
Start: 08/31/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/19/16
End: 10/01/21
Due: 10/01/22
Phase: N/A
Priority: Normal
Start: 06/14/18
End: 03/04/21
Due: 03/04/22
Phase: N/A
Priority: Normal
Start: 07/10/18
End: 06/25/19
Due: 06/25/20
Phase: N/A
Priority: Normal
Start: 05/31/04
End: 08/31/12
Due: 08/31/13
Phase: N/A
Priority: Normal
Start: 03/04/20
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 10/16/20
End: 07/01/26
Due: 07/01/27
Phase: N/A
Priority: Normal
Start: 09/17/15
End: 08/20/19
Due: 08/20/20
Phase: N/A
Priority: Normal
Start: 09/30/03
End: 09/30/09
Due: 09/30/10
Phase: N/A
Priority: Normal
Start: 08/31/05
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/17/14
End: 12/18/18
Due: 12/18/19